APLS stock jumps 140% after Biogen announces $5.6 bn acquisition

Apellis Pharmaceuticals (APLS) stock soared 140% pre-market after Biogen agreed to acquire the company for $5.6 billion. The deal aims to bolster Biogen's rare-disease portfolio and expand its nephrology footprint. Retail sentiment on Stocktwits turned bullish on the massive acquisition news.